<DOC>
	<DOCNO>NCT01577654</DOCNO>
	<brief_summary>This study test activity single-agent EC145 combination EC145 plus docetaxel current standard docetaxel second line Non Small Cell Lung Cancer ( NSCLC ) ( adenocarcinoma , squamous , adenosquamous adenocarcinoma NSCLC variant lung ) participant target lesion express folate receptor [ FR ( ++ ) ] .</brief_summary>
	<brief_title>Phase 2 Study EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone Participants With FR ( ++ ) 2nd Line Non Small Cell Lung Cancer</brief_title>
	<detailed_description>In phase 2 study single-agent EC145 heavily pretreated non-small cell lung cancer ( NSCLC ) patient ( median 3 prior chemotherapy regimen ) , subgroup target lesion express folate receptor [ FR ( ++ ) ] promise prolonged progression free survival 7.1 month overall survival 10.9 month . Furthermore , in-vitro in-vivo study KB model show good synergism EC145 docetaxel . This study clinically ass first time combination EC145+docetaxel ( Arm B ) participant NSCLC ( Stage IIIB IV ) . This international , multicenter , centrally randomize , open-label , phase 2 study compare single-agent EC145 , EC145+docetaxel combination therapy , single-agent docetaxel participant NSCLC fail one prior chemotherapy target lesion express folate receptor [ FR ( ++ ) ] . Eligible participant randomize 1:1:1 ratio either Arm A ( single-agent EC145 ) , Arm B ( EC145+docetaxel combination therapy ) , Arm C ( single-agent docetaxel ) receive treatment either disease progression intolerable toxicity . This study intend investigate sufficiently strong efficacy signal order proceed phase 3 test either EC145 single-agent and/or combination EC145+docetaxel standard-of-care docetaxel second-line NSCLC . This study clinically ass first time combination EC145+docetaxel ( Arm B ) participant NSCLC ( Stage IIIB IV ) . Therefore , interim safety analysis do DSMB 5 participant Arm B complete 1 cycle therapy , second analysis 15 participant Arm B complete 1 cycle therapy . If majority enrol participant ( 70 % ) require dose reduction one level ( 60 mg/m2 ) , dose reduce remainder study . If majority participant ( 70 % ) require 2 dose reduction ( 40 mg/m2 ) , sponsor consider discontinue combination arm .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinca Alkaloids</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>1 . Ability sign approve informed consent form ( ICF ) . 2 . Must ≥ 18 year age . 3 . Histology confirm diagnosis nonsmall cell lung cancer ( adenocarcinoma , squamous , adenosquamous , adenocarcinoma NSCLC variant lung ) ( Stage IIIB IV ) . 4 . All ( RECIST v1.1defined ) target lesion positive folate receptor [ FR ( ++ ) ] SPECT scan . 5 . Only one prior systemic therapy advance disease ( e.g. , platinum doublet maintenance regimen include platinum doublet ; addition , participant may receive epidermal growth factor receptor [ EGFR ] inhibitor ) . 6 . Radiological evaluation conduct 28 day prior begin study therapy . If history CNS metastasis baseline radiological imaging must include brain MRI CT. 7 . Radiologic evidence disease progression follow recent prior treatment . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 9 . Must recover ( baseline/stabilization ) prior cytotoxictherapyassociated acute toxicity . 10 . Prior radiation therapy allow follow criterion meet : Radiation &lt; 25 % bone marrow ; whole pelvis radiation exclude . Prior radiotherapy must complete least 2 week randomization . Must recover acute toxic effect treatment randomize . Prior thoracic radiation must complete 30 day study enrollment . Irradiated pulmonary lesion use target nontarget lesion ( must exclude ) unless previous document progression lesion . Palliative extrathoracic radiotherapy continue , lesion must exclude target nontarget lesion . 11 . Adequate organ function : Bone marrow reserve : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L . Platelets ≥ 100 x 109/L . Hemoglobin ≥ 9 g/dL . Hepatic : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gamma glutamyl transferase ( GGT ) , lactate dehydrogenase ( LDH ) alkaline phosphatase ≤ 2.5 x ULN . Renal : Serum creatinine ≤ 1.5 x ULN , participant serum creatinine &gt; 1.5 ULN , creatinine clearance ≥ 50 mL/min/1.73 m2 ( 50mL/min/1.73m2 equivalent 0.83 mL/s/m2 ) . 12 . Participants childbearing potential : Women capable become pregnant must negative serum pregnancy test within 1 week prior exposure EC20 within 1 week prior exposure treatment EC145 and/or docetaxel . Women capable become pregnant male participant sexually active must practice effective method birth control duration participation trial 3 month follow last dose EC145 6 month follow last dose docetaxel . 1 . Prior therapy docetaxel , vinorelbine , vincacontaining compound . 2 . Known hypersensitivity docetaxel polysorbate 80 . 3 . Symptomatic central nervous system ( CNS ) metastases metastasis result midline shift , significant edema . 4 . Malignancies NSCLC expect alter life expectancy may interfere disease assessment . Patients adequately treat nonmelanoma skin cancer , carcinoma situ cervix , lowgrade ( Gleason score ≤ 6 ) localize prostate cancer patient prior history malignancy disease free 3 year eligible . 5 . Serious cardiac illness medical condition unstable angina , pulmonary embolism , uncontrolled hypertension . 6 . Antifolate therapy methotrexate rheumatoid arthritis . 7 . Baseline peripheral neuropathy CTCAE ≥ Grade 2 . 8 . Pregnant lactating woman . 9 . Other concurrent chemotherapy , immunotherapy , radiotherapy , investigational therapy . 10 . Active infection ( e.g. , hepatitis HIV carrier )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>squamous</keyword>
	<keyword>adenosquamous</keyword>
	<keyword>adenocarcinoma NSCLC variant</keyword>
	<keyword>EC145</keyword>
	<keyword>EC20</keyword>
	<keyword>Vintafolide</keyword>
	<keyword>Etarfolatide</keyword>
</DOC>